Search results for "Highlights"
One-time serum C-peptide testing detected patients misclassified as having type 1 diabetes
In a recent study, a serum C-peptide testing program resulted in reclassification of the cause of diabetes in about 7% of the cohort tested at one diabetes center in Scotland. Reclassification was most likely in those diagnosed at age 30 years or older.
https://diabetes.acponline.org/archives/2020/11/13/2.htm
13 Nov 2020
New guideline from Endocrine Society offers guidance on lipid management
The guideline includes recommendations on the use of statins and lipid testing in type 1 and 2 diabetes, as well as other endocrine-related diseases and conditions.
https://diabetes.acponline.org/archives/2020/11/13/1.htm
13 Nov 2020
AHA scientific statement reviews research on drugs for diabetes and chronic kidney disease
The advent of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists could reduce cardiovascular adverse events and progression to end-stage kidney disease, the American Heart Association (AHA) scientific statement noted.
https://diabetes.acponline.org/archives/2020/10/09/2.htm
9 Oct 2020
Patients with type 2 diabetes at higher risk for AKI, even without pre-existing kidney disease
The authors of the retrospective study called for additional research on the pathogenesis of acute kidney injury (AKI) and the associated risk factors, such as medications, in diabetic patients.
https://diabetes.acponline.org/archives/2020/10/09/3.htm
9 Oct 2020
SGLT-2 inhibitors linked to lower risk of cardiac events compared with DPP-4 inhibitors
A retrospective study of Canadian and British patients with type 2 diabetes found lower rates of cardiovascular death among those taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors than in matched patients who took dipeptidyl peptidase-4 (DPP-4) inhibitors.
https://diabetes.acponline.org/archives/2020/10/09/1.htm
9 Oct 2020
Recent-onset diabetes, weight loss associated with increased pancreatic cancer risk
Unintentional weight loss and weight loss in those with a body mass index already in the normal range were particularly associated with risk of pancreatic cancer among patients with recent-onset diabetes, a study found.
https://diabetes.acponline.org/archives/2020/09/11/2.htm
11 Sep 2020
Adverse events associated with SGLT-2 inhibitors do not appear dose-dependent
In a systematic review and meta-analysis, no difference was seen between high- and low-dose sodium-glucose cotransporter-2 (SGLT-2) inhibitors in overall safety or specific safety outcomes, other than a mild increased risk for adverse events with higher doses of canagliflozin.
https://diabetes.acponline.org/archives/2020/09/11/3.htm
11 Sep 2020
Weight loss through gastric bypass or diet improved insulin sensitivity in patients with type 2 diabetes
Results from this small study suggest that reducing adipose tissue volume, by whatever means, will improve blood glucose control in patients with type 2 diabetes, an accompanying editorial noted.
https://diabetes.acponline.org/archives/2020/09/11/1.htm
11 Sep 2020
SGLT-2 inhibitors associated with increased risk for diabetic ketoacidosis
A cohort study found a threefold increase in the risk for diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT-2) inhibitors compared to dipeptidyl peptidase-4 (DPP-4) inhibitors, with possible variation by severity or duration of diabetes.
https://diabetes.acponline.org/archives/2020/08/14/2.htm
14 Aug 2020
Patient-led titration of basal insulin appears effective in type 2 diabetes
A meta-analysis of six studies found that patient-led titration was associated with lower HbA1c and fasting plasma glucose levels than physician-led titration, although hypoglycemia risk and body weight were slightly higher.
https://diabetes.acponline.org/archives/2020/08/14/3.htm
14 Aug 2020